Sign in
Not yet taking people in United StatesPhase 3

Early ketamine for pain in young people with sickle cell disease

Tests early ketamine for pain from sickle cell disease, checking hospital admission.

Key facts

Who runs it
Boston Children's Hospital
Where
Brookline, United StatesSee the site
Trial code
Registry title
Optimal Timing of Ketamine Initiation for SCD Pain
Status
Not yet recruiting
Phase
Phase 3
People taking part
90 people, planned
Started
Feb 2026
Expected to end
Feb 2030
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Ketamine hydrochloride injection
  • Placebo
Record updated
9 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young adults with sickle cell disease who come to the emergency department or infusion clinic with pain.

Age
6 to 24 years old
Sex
All sexes can join.
Disease stage
Sickle cell disease with pain at the time of the visit to the emergency department or infusion clinic.

Main reasons for not taking part

  • Allergy to ketamine
  • Severe side effects from ketamine in the past
  • Unable to give consent

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • sickle cell disease diagnosis
  • presenting with pain to ED or infusion clinic
  • patient at study site
  • 6 to 24 years old

Who cannot take part

  • allergy to ketamine
  • severe side effects associated with ketamine
  • unable to consent

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 6 and 24 years old?

Where in United States

  • Boston Children's HospitalBrookline, United StatesContact: Natasha ArcherNot yet recruiting

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if the use of early ketamine decreases the chance of admission to the hospital in patients with sickle cell disease presenting with pain.

Read full original descriptionShow less

The main questions this study aims to answer are:

* Does ketamine given within 1 hour of acute care presentation decrease the chance of hospital admission? * If admitted, does continuing ketamine in the first few hours of admission decrease opioid use or length of stay compared to those who start it later in the admission?

Researchers will compare the study arm to patients with sickle cell disease who receive placebo within 1 hour of presentation for the first aim.

Participants will be given ketamine/placebo by mouth without 1 hour of presentation.

If admitted, all participants will be able to start open label IV ketamine upon admission to the floor based on their clinical needs. Participants who end up starting ketamine will be reviewed to determine if early start to ketamine is helpful in reducing opioid use and length of stay.

The 2 groups in the trial

  • Oral KetamineTreatment being tested

    Single dose of oral ketamine 0.5mg/kg (max dose of 35mg)

    Treatment: Ketamine hydrochloride injection

  • PlaceboPlacebo, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Double-blind, Randomized, Placebo Controlled Study to Evaluate Optimal Timing of Ketamine Initiation
Plain-language title
Early ketamine for pain in young people with sickle cell diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Fit questions
Built from NCT07450430, who can take part
Record updated
9 March 2026